Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Celldex Therapeutics Is Jumping Today

By Keith Speights - Dec 10, 2018 at 12:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There's nothing to get excited about with this clinical-stage biotech stock's double-digit-percentage gain.

What happened

Shares of Celldex Therapeutics ( CLDX -5.28% ) jumped 12.1% higher as of 11:22 a.m. EST on Monday. The biotech made no announcements. There really wasn't any news to serve as a catalyst for the stock. So what sparked Celldex's move higher? What we're probably seeing is typical volatility in a small clinical-stage biotech stock.

So what

As you might suspect, Celldex's jump today doesn't really mean anything. There have been several other double-digit-percentage daily increases for the biotech stock over the last four months. Those surges didn't mean anything, either.

Hand holding flask with dropper, test tubes, and other lab glassware.

Image source: Getty Images.

The big percentage jump for Celldex today amounted to an increase in its share price of around $0.03. Relatively small price changes have significant impacts on stocks with low share prices. And Celldex's share price has been below $1 since the company announced in April that its lead candidate glembatumumab vedotin (glemba) failed in a mid-stage clinical study.

Small clinical-stage biotech stocks often spike on no news at all. The bad news is that they can also drop on no news at all.

Now what

What really matters for Celldex over the long run is its pipeline. The next big news on that front will come in the first quarter of 2019, when Celldex expects to announce results from the first part of a phase 2 study of CDX-3379 in treating advanced head and neck squamous cell cancer.

However, the key thing for investors to watch is what Celldex does to retain its listing on the Nasdaq Global Market stock exchange, which requires listed stocks to maintain a $1 minimum bid price. Celldex is likely to implement a reverse stock split, a move that would reduce the number of shares outstanding and boost the stock price.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Celldex Therapeutics, Inc. Stock Quote
Celldex Therapeutics, Inc.
CLDX
$36.09 (-5.28%) $-2.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
656%
 
S&P 500 Returns
144%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/02/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.